EA
CLCD

Emerald Acquisition’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Emerald Acquisition’s Portfolio CLCD Stock Details CLCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$2.22M Buy
+58,296
New +$862K ﹤0.01% 1691

Other funds holding CLCD

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Emerald Acquisition's CLCD Position: Q3 2016 in Review

Emerald Acquisition opened a new position in CoLucid Pharmaceuticals, Inc. (CLCD) in Q3 2016: 58,296 shares worth $2.22M. The stake represents ﹤0.01% of the portfolio and ranks #1691 among its holdings.

56 funds tracked by Wall St. Rank hold CLCD as of Q3 2016.

  • Emerald Acquisition held 58,296 shares of CoLucid Pharmaceuticals, Inc. worth $2.22M as of Q3 2016.
  • CoLucid Pharmaceuticals, Inc. was a new Emerald Acquisition position in Q3 2016.
  • CoLucid Pharmaceuticals, Inc. made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1691 holding.
  • 56 funds tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.